Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01610 in extensive-stage small cell lung cancer
NCT04381910Phase 2Completed
- Sponsor
- Luye Pharma Group
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome in small cell lung cancer (SCLC), sponsored by Luye Pharma Group. Primary endpoints: Objective Response Rate at 12 months and Duration of Response at 12 months. Started Sep 2020; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04381910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381910.